Am­gen's block­buster hope­ful Lumakras sees slow­er than ex­pect­ed sales in lat­est da­ta, an­a­lyst says

It’s been on­ly about one year since Am­gen’s KRAS-tar­get­ed NSCLC drug Lumakras has been mar­ket­ed in the US, and al­ready an­a­lysts are warn­ing of wan­ing sales for the block­buster hope­ful.

A re­port from SVB Se­cu­ri­ties on Mon­day said Lumakras’ Q2 sales didn’t come in as high as ex­pect­ed, with the an­a­lysts low­er­ing US sales pro­jec­tions by 8%, from $60 mil­lion to $55 mil­lion, for the last quar­ter.

Al­so known as so­tora­sib, the drug won ap­proval last May to treat types of non-small cell lung can­cer with the KRAS G12C mu­ta­tion, beat­ing com­peti­tor Mi­rati Ther­a­peu­tics to the reg­u­la­to­ry fin­ish line. At the time, an­a­lysts pre­dict­ed the drug would se­cure more than $1 bil­lion in peak sales, with a list price of $17,900 a month.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER